Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + cisplatin with IMRT in locally advanced head and neck squamous cell carcinoma
ChiCTR2300078096Phase 4Recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib in head and neck squamous cell carcinoma (HNSCC), sponsored by First People's Hospital of Lianyungang City. Primary endpoints: Maximal tolerated dose of fluzoparib and Dose-limiting toxicity (DLT) of fluzoparib. Started Nov 2023; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300078096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078096.